有效抗癌药物定价过高致承诺落空
本文为评论文章,以ASCO 2026报道的RASolute302试验为例,该试验在经治晚期胰腺癌患者中显示daraxonrasib较化疗延长中位总生存7个月并改善生活质量,但作者指出有效抗癌药物定价超出可及范围,其承诺未能兑现。
要点
- RASolute302试验中daraxonrasib较化疗延长经治晚期胰腺癌中位总生存7个月。
- 该药同时改善生活质量,被视为胰腺癌靶向治疗的里程碑。
- 评论指出有效抗癌药物定价过高,可及性承诺未兑现。
核心结论
- 有效抗癌药物若定价超出可及范围,其临床承诺无法兑现。
研究设计与样本
- 本文为评论文章,引用ASCO 2026报道的RASolute302试验结果进行论述。
主要发现
- 在经治晚期胰腺癌患者中,daraxonrasib较化疗延长中位总生存7个月并改善生活质量。
- 胰腺癌靶点此前被认为不可成药,该治疗被视为药物开发的里程碑成功。
临床怎么用
- 关注新药疗效同时需评估定价对患者可及性的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Every year, pivotal clinical trials are reported, showing major advances in cancer treatment. At the American Society of Clinical Oncology (ASCO) 2026 conference, results from the RASolute302 trial for patients with advanced pancreatic cancer established daraxonrasib, a RAS(ON) inhibitor, as a watershed moment in oncology.1 Among previously treated patients, daraxonrasib improved median overall survival by 7 months compared with chemotherapy and improved quality of life. Given that pancreatic cancer is among the most lethal of all cancers, the target was hitherto considered undruggable, and that the disease is accompanied by considerable suffering, this treatment was appropriately celebrated as a landmark success of drug development.
引用
- Lancet Oncology:[Comment] The unfulfilled promise of effective cancer medicines priced beyond reach
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。